Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study

MLA

Taylor, Sarah A., et al. “Phase II Evaluation of Mitoxantrone in Advanced Pancreatic Carcinoma: A Southwest Oncology Group Study.” Investigational New Drugs, vol. 8, no. 1, Mar. 1990, pp. 77–80. EBSCOhost, https://doi.org/10.1007/BF00216928.

APA

Taylor, S. A., Fleming, T., Hoff, D. D., McCracken, J. D., Bukowski, R. M., Talley, R. W., Natale, R. B., Guy, J. T., Samlowski, W. E., & Costanzi, J. H. (1990). Phase II evaluation of mitoxantrone in advanced pancreatic carcinoma: A Southwest Oncology Group study. Investigational New Drugs, 8(1), 77–80. https://doi.org/10.1007/BF00216928

Chicago

Taylor, Sarah A., Thomas Fleming, Daniel D. Hoff, Joseph D. McCracken, Ronald M. Bukowski, Robert W. Talley, Robert B. Natale, J. T. Guy, Wolfram E. Samlowski, and John H. Costanzi. 1990. “Phase II Evaluation of Mitoxantrone in Advanced Pancreatic Carcinoma: A Southwest Oncology Group Study.” Investigational New Drugs 8 (1): 77–80. doi:10.1007/BF00216928.